Abstract
AbstractOptimal diagnosis and management of children aged <15 y with rifampicin- or multidrug-resistant tuberculosis (RR/MDR-TB) relies on identification of adults with the disease and pro-active screening of their close contacts. Children may be diagnosed with RR/MDR-TB based on microbiological confirmation from clinical specimens (sputum, gastric washings, stool), but usually the diagnosis is presumptive, with a history of exposure to RR/MDR-TB and clinical/radiological signs and symptoms suggestive of TB disease. RR/MDR-TB should also be considered in children where first-line TB treatment fails despite good adherence to therapy. Composition and duration of all-oral RR/MDR-TB treatment regimens in children are based on site and severity of TB disease, drug resistance profile of the Mycobacterium tuberculosis strain (isolated from the child or from the most likely source patient), inclusion of at least four drugs considered to be effective (with priority given to World Health Organization Group A and B drugs), toxicity and tolerability of medications (and feasibility of adverse effect monitoring in the child’s setting), and availability of child-friendly formulations of TB medications. Individualized RR/MDR-TB regimens are preferable to the standardised 9–12-mo regimen for children, and injectable agents must not be used. Optimal adherence to treatment relies on education, training and support for caregivers and others who are responsible for administering medications to children, as well as close clinical monitoring and early management of adverse effects. Children who are initiated on adequate RR/MDR-TB regimens have high treatment success rates, but efforts to find and treat more children with undiagnosed RR/MDR-TB are crucial to reduce childhood TB mortality.
Funder
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Stellenbosch University
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference42 articles.
1. Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2018;22:3–6.
2. World Health Organisation. Global tuberculosis report 2022. Geneva, Switzerland: WHO; 2022. Available at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. Accessed 27 July 2023
3. World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020. Geneva, Switzerland: WHO; 2021. Available at: https://www.who.int/publications/i/item/9789240018662. Accessed 27 July 2023.
4. Schaaf HS. Diagnosis and management of multidrug-resistant tuberculosis in children: a practical approach. Indian J Pediatr. 2019;86:717–24.
5. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of drug-resistant tuberculosis in children: a field guide. 5th ed. Boston, USA: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis; November 2021. Available at: http://sentinel-project.org/wp-content/uploads/2022/04/DRTB-Field-Guide-2021_v5.1.pdf. Accessed 10 July 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献